December 2018 just isn't any month. December 2018 may be the time when the 100% of events has been reached and dosing ends. Recall at the AGM and BIO-Europe, Resverlogix expected last dosing by end of 2018. Of course, this may creep into early 2019 since hitting the 250 event mark is out of management's control. Hopefully by Biotech Showcase in early January Resverlogix will have met this milestone. 

Iconoclast posted earlier "My pet peeve is that RVX is not listed on the Nasdaq.  For it to do another Amarin, a Nasdaq listing is a sine qua non.  If they wait for Phase 3 results to come through and then list on the Nasdaq, that will be a damp squib.  They should list asap...and then see the magic of lustful US buyers driving it up"

I assume you are referring to top-line data. There are more milestones & announcements between now and top-line data release that have potential to impact the share price in a way that makes it easier to move to the Nasdaq prior to top-line data. 8th DSMB report, end of dosing, last patient study visit.......these are all things that will narrow the bookends and potentially bring more attention to Resverlogix and BETonMACE. Also, keep in mind that a delay in between top-line data announcment and full data results is very possible depending upon what meeting Resverlogix plans to present full data at. This time period between top-line data and full data presentation could also present an opportunity for the share price to pop at top-line, allowing an easier transition to Nasdaq prior to full data, and once on Nasdaq potentially another pop leading up to and at full data presentation.

BDAZ